Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus EXDENSUR.
Head-to-head clinical analysis: ACTONEL WITH CALCIUM COPACKAGED versus EXDENSUR.
ACTONEL WITH CALCIUM (COPACKAGED) vs EXDENSUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
EXDENSUR (generic name not specified) is a novel oral anticoagulant that selectively inhibits activated factor XI (FXIa), thereby reducing thrombin generation and preventing clot formation without significantly affecting hemostasis.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
5 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Terminal elimination half-life is 8 hours in healthy adults, prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 mL/min.
Primarily renal excretion of unchanged drug (85%) and minor biliary excretion (15%). Total clearance is 120 mL/min.
Category C
Category C
Bisphosphonate and Calcium Supplement
Bisphosphonate